BCX7353-302:Phase 3 randomized doubleblind placebo controlled parallel group study evaluate efficacy&safety of 2-dose levels BCS7353 as oral treatment for prevention of attacks w/hereditary angioedema
Clinical Trial Grant
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Biocryst Corporation
Start Date
February 15, 2018
End Date
March 15, 2019
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Biocryst Corporation
Start Date
February 15, 2018
End Date
March 15, 2019